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sympathetically cured by ABVD with the remaining onethird suffering threatening disease recurrence.
To the aim of tailoring optimal strategies to eradicate cHL while avoiding worrying side effects, the identification of robust, 'easy to assay' and reproducible biomarkers could support the adoption of different intensities in treatment according to various risk profiles. Hitherto, none of the various prognostic biomarkers identified in Hodgkin lymphoma have demonstrated predictive capacities (Steidl et al, 2011) to help define different patient risk categories and to assist in providing treatment according to the best trade-off of toxicity and efficacy.
This challenge still stands following the dismal results of recent clinical trials exploring interim fluorodeoxyglucose positron emission tomography (iPET) as a biomarker to differentiate good and poor responders during treatment and eventually early institute alternative therapeutic strategy (Borchmann et al, 2017) .
Many reports have shown that dendritic cells (DCs), the main antigen-presenting cells, play a crucial role in promoting the host immune response against tumours by an efficient cross-presentation of tumour antigen (Steinman et al, 1975; Banchereau et al, 2000; Chan & Housseau, 2008; Steinman, 2012) .
DCs derive from progenitor cells in the bone marrow through haematopoiesis and are found in blood, lymphoid organs and all tissues. In humans, DC subtypes in the blood include CD11C + conventional DCs (cDCs), consisting of either (Rovati et al, 2008; Ziegler-Heitbrock et al, 2010; Reizis et al, 2011; Tel et al, 2012) . mDCs play a basic role in pathogen sensing, antigen presentation to T lymphocytes and antigen-specific stimulation of CD4 + and CD8 + T cells (Segura & Villadangos, 2009) . pDCs exert potent antiviral activity by the production of Type-I interferon and contribute to anti-tumour responses through their synergistic interaction with mDCs. While studies have extensively investigated the clinico-biological relevance and prognostic significance of several nonneoplastic cell types of the cHL microenvironment, the role of DCs as possible mediators of immune escape, and/or tumour progression has been less explored (Aldinucci et al, 2010; Scott & Gascoyne, 2014) .
In this study, we used multi-parametric flow cytometry to explore the frequency of blood DCs in cHL patients at the onset of their disease and the end of their chemotherapy induction treatment. Correlation with the main prognostic factors was performed.
Material and methods

Patients and controls
Fifty-two patients with cHL diagnosed according to the World Health Organization classification (Campo et al, 2011) were prospectively enrolled at the Department of Haematological Oncology Division of the National Cancer Institute "Pascale Foundation" in Naples, Italy. The study protocol was approved by the local Ethics Committee and conformed to the Declaration of Helsinky. Each participant provided written informed consent for biological testing.
All patients were eligible if they had untreated, biopsyproven cHL. Pre-treatment evaluation comprised a laboratory workup, chest X-ray, total body contrast-enhanced computed tomography (CT), bone marrow biopsy and fluorine-18-fluorodeoxyglucose (FDG) -positron emission tomography (PET).
Patients were staged according to Ann Arbor system as modified at Cotswolds meeting 3 and evaluated for the prognostic relevance of extension of disease through the German Hodgkin Study Group (GHSG) score system for early stages and the International Prognostic Score for advanced stages (Lister et al, 1989; Hasenclever & Diehl, 1998; Franklin et al, 2000; Josting & Diehl, 2001; Cheson et al, 2014) .
All patients were treated with 'ABVD' (adriamycin, bleomycin, vinblastine, and dacarbazine). Interim disease evaluation (after the first two cycles of treatment) and restaging 1 month after the end of treatment (EOT) and at 3-6 months after that were performed with FDG-PET/CT. Response assessment was conducted as per the International Working Group response criteria (Cheson et al, 1999; Cheson, 2007) .
Twenty-nine age-and gender-matched healthy volunteers were recruited as controls. Smokers and individuals with abnormal BMI and blood pressure were excluded, as were those with a history of cancer, allergies, inflammatory or autoimmune disease, or infectious disorders.
Phenotypical analysis of circulating DC subsets
A DC enumeration kit (Blood Dendritic Cell Enumeration Kit, Milteny Biotech, Bergisch Gladbach, Germany) was used to identify by flow cytometry the DC subtypes, according to the manufacturer's instructions. Reference median frequencies of blood DC subsets were 0Á27 (range, 0Á09-0Á42), 0Á02 (range, 0-0Á04), 0Á19 (range, 0Á09-0Á37) for mDC1, mDC2 and pDC, respectively.
Briefly, 300 ll of EDTA-treated whole blood was incubated for 10 min with a cocktail of monoclonal antibodies (mAbs) including anti-CD1c (phycoerythrin, PE) (mDC1 marker), anti-CD141 (allophycocyanin, APC) (mDC2 marker) and anti-CD303 (fluorescein isothiocyanate, FITC) (pDC marker). Mouse IgG2a-PE, IgG1-FITC, and IgG1-APC Abs were used as isotype controls. Samples were co-stained with CD19-PE-Cy-5 and CD14-PE-Cy5 to exclude B cells and monocytes from the analysis and a dead-cell discriminator was utilized in all specimens. After staining and erythrocyte lysis, cells were washed and fixed. Samples (5 9 10 5 events/sample) were acquired on a FACS Canto II The relative and absolute number of DCs were calculated and compared among different groups. Blood samples were withdrawn at baseline, no more than 14 days before the start of the treatment, and at least 3 weeks after treatment completion.
Statistics
Statistical analyses were performed using R environment for statistical computing (version 3.2.3) (R Core Team 2015) . Quantitative variables were characterized using median with quartile ranges while categorical factors were described with absolute frequencies and percentages. Accordingly, the comparison between cHL patients and healthy controls were based on the Mann-Whitney U test or the Chi-Square test. A median regression model was further used to obtain gender and age-adjusted comparison. The significance of the change in circulating blood DC subsets in cHL patients following chemotherapy treatment was assessed using Wilcoxon signed-rank test. Correlations among quantitative variables were based on the non-parametric Spearman rank correlation coefficient. Kaplan-Meyer analysis (log-rank test) for survival was performed using GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA, USA). All tests were two-sided and statistical significance was set at P < 0Á05.
Results
Patient characteristics
Patients characteristics are listed in Table I . The median age was 34 years (range, 19-66 years); 23 patients (44Á2%) had early stage (i.e., I, IIA/B, IIA extranodal or bulky), while 29 (55Á8%) had advanced stage (i.e., IIB extranodal or bulky, III and IV). B-symptoms were recorded in 46% of patients, whereas 21 patients (40Á4) had more than three affected lymph node regions according to the Ann Arbor staging system.
Bulky disease was present in 24 patients (46Á1%) and located in the mediastinum (maximum width >1/3 of thoracic diameter) in 18 (34Á6%). Among the 23 patients with early-stage disease, 48% had 3 or more nodal sites according to GHSG criteria while 45% of those with advanced stage had an IPS score of 3-7. iPET after the first two cycles (PET2) was negative in 47 patients.
At a median follow up of 33Á5 months, one primary progression and two relapses (<12 months: N = 1; >12 months: N = 1) had occurred.
Levels of circulating DC subsets in cHL at diagnosis
Flow cytometric estimates of frequencies of circulating DC subsets among total leucocytes were performed in all 52 cHL patients and the 29 healthy subjects. As expected, leucocyte counts significantly differed between the controls [median 7Á0 9 10 9 /l (25th; 75th percentile: 5Á71; 7Á95 9 10 9 /l)] and the cHL patients [median 9Á52 9 10 9 /l (25th; 75th percentile:
7Á53; 12Á82 9 10 9 /l) (P < 0Á001), and cHL patients were more frequently lymphocytopenic [median 1Á7 9 10 9 /l (25th; 75th percentile: 1Á1; 1Á82 9 10 9 /l)], as compared with healthy controls [median 2Á25 9 10 9 /l (25th; 75th percentile: 2Á1;
2Á65 9 10 9 /l)] (P < 0Á001). A more marked reduction was observed in the CD20 + subset with a median of 0Á083 9 10 9 / l (25th; 75th percentile: 0Á041; 0Á125 9 10 9 /l) as compared with 0Á3 9 10 9 /l (25th; 75th percentile: 0Á229; 0Á482 9 10 9 / l)] recorded in the healthy control group (P < 0Á001).
The distributions of the percentages and total amounts of mDC1, mDC2, and pDC subsets are detailed in Fig 1. In the control group, the relative and absolute median counts (25th; 75th percentile) for the different DCs subsets were respectively 0Á160 (0Á06; 0Á3) and 0Á01114 9 10 9 /l (0Á00346; 0Á02471 9 10 9 /l) for mDC1, 0Á020 (0Á01; 0Á02) and 0Á001 9 10 9 /l (0Á0065-0Á00191 9 10 9 /l) for mDC2, 0Á230 (0Á16; 0Á32) and 0Á00515 9 10 9 /l (0Á0023-0Á00825 9 10 9 /l) for pDC. In the 52 cHL patients, the relative and absolute median counts (25th; 75th percentile) for the different DC subsets were respectively 0Á050 (0Á02; 0Á09) and 0Á00436 9 10 9 /l (0Á00212; 0Á00777 9 10 9 /l) for mDC1, 0Á006 (0Á003; 0Á009) and 0Á0006 9 10 9 /l (0Á00031-0Á00088 9 10 9 /l) for mDC2, 0Á056 (0Á029; 0Á089) and 0Á00515 9 10 9 /l (0Á0023-0Á00825 9 10 9 /l) for pDC.
For all the DC subsets, the median percentages and absolute counts were significantly lower in cHL patients as compared with healthy controls (P < 0Á001). Frequencies of mDC1 and mDC2 subsets were widely scattered among cHL patients, reaching very low percentages and were undetectable in some cases.
DC levels and extent of disease
The distribution of the DC subsets in the 52 patients was analysed according to the conventional indicators of disease extent and the data are summarised in Table II . Percentage counts differed significantly according to disease anatomical extent and were lower for the advanced stage, as compared with early stage, for both mDC1 (0Á030 vs. 0Á070; P = 0Á008) and mDC2 (0Á005 vs. 0Á009; P = 0Á001) subsets. Also, the percent mDC2 cell rates were significantly reduced in patients with bulky (0Á004 vs. 0Á008; P = 0Á0004) or extranodal (0Á005 vs. 0Á006; P = 0Á047) disease. No statistically significant differences were observed for pDC subset across the different indicators of the anatomical extent of disease.
Patients with B-symptoms had significantly lower levels of both myeloid subsets (mDC1: P = 0Á046; mDC2: P = 0Á009) and pDCs (P = 0Á040).
Circulating DC subsets at the end of treatment
In 26 cHL patients, the frequencies of blood mDCs and pDCs at the time of diagnosis (T0) were compared with those obtained at EOT.
The analysis showed that the EOT median (25th; 75th percentile) percentages of mDC1, mDC2 and pDC subsets were significantly higher in comparison with those at diagnosis, rising from 0Á038 to 0Á168 (0Á103; 0Á250) (P < 0Á0001), 0Á005 to 0Á012 (0Á006; 0Á020) (P < 0Á0001) and 0Á042 to 0Á190 (0Á110; 0Á304) (P < 0Á0001), respectively (Fig 2) . The increases from basal to EOT values were 4Á6-fold (+364%) for mDC1, 2Á4-fold (+140%) for mDC2 and 4Á5-fold (+352%) for pDC and led all the DC subsets to values aligned with those of interquartile ranges of healthy controls.
EOT recovery of DCs was independent of any of the usual negative prognosticators/predictors, including positive PET2 (Table III) .
Survival analysis
Kaplan-Meyer analysis of progression-free survival (PFS) was performed for the cohort of 29 patients with advanced stages of the disease, at a median time of 33Á5 months follow-up.
We used the median value of the DC counts to group patients as having low or high DC counts. Upon stratification, no significant difference was observed in terms of PFS between patients with low or high mDC and pDC levels.
Discussion
The quantitative reduction of blood DCs and their dysfunction, due either to an impaired maturation capacity or allostimulatory activity, have been documented in different haematological malignancies, such as chronic lymphocytic leukaemia (Orsini et al, 2003) , hairy cell leukaemia (Bourguin-Plonquet et al, 2002) , acute lymphoblastic leukaemia (Mami et al, 2004) , multiple myeloma (Ratta et al, 2002; Brimnes et al, 2006) and chronic myeloid leukaemia (Mohty et al, 2002; Dong et al, 2003; Boissel et al, 2004; Galati et al, 2016) .
Here, we report results of a study investigating frequency and profiles of blood DCs in adult cHL patients and healthy gender-and age-matched controls. We provided statistical evidence for (i) lower numbers of blood mDCs and pDCs in cHL patients as compared to healthy controls, (ii) reduced numbers of both mDC subtypes in patients with advanced stage disease, (iii) a wider anatomical extent of disease, as indicated by the presence of extranodal or bulky disease in patients with low mDC2 levels, (iv) increases in all DC subsets at EOT with final recovery levels similar to those of the healthy controls. Although no data on blood mDCs in cHL are available to date, a recent report has shown lower absolute counts of pDCs, as compared with controls, in a small cohort of 10 patients with untreated cHL (Shodell et al, 2014) .
The reduction of DCs in the blood of cHL patients may be either due to peripheral depletion caused by cell displacement into lymphoid organs, prompted by HRS cells, released chemokines or a decreased production of haematopoietic stem cells (Maggio et al, 2002; Fhu et al, 2014 ; Aldinucci Boxplot showing the distribution expressed in quartiles of relative (top) and absolute (bottom) counts of mDC1, mDC2 and pDC subsets among total leucocytes in 52 HL patients at diagnosis and 29 healthy volunteers. P-values were obtained using median regression adjusted for age and gender. HL, Hodgkin lymphoma; mDC1, myeloid dendritic cells type 1; mDC2, myeloid dendritic cells type 2; pDC, plasmacytoid dendritic cells.
et al, 2016). The attraction between many of these cells from the peripheral circulation and their interactive neoplastic cells is probably a critical factor for the survival and proliferation of HRS cells (Aldinucci et al, 2010) . It is unclear why the DC balance should be perturbed at the time of cHL diagnosis. It could be that immune dysfunction, occurring in cHL patients, changes DCs ability to migrate into lymphoid organs. One of the most relevant observations from our study dealt with mDC2 cells. The quantitative reduction of these cells at diagnosis seemed to parallel the anatomical extent of disease, with a statistically significant reduction in frequencies for patients with advanced stage disease as well as in the presence of extranodal and bulky disease. In addition, we observed that the three total recurrences all had a low mDC2 absolute count and that the increase of total mDC2 numbers upon treatment completion was less complete and impressive (P = 0Á078) in comparison with mDC1 and pDC subsets. Therefore, one may argue that mDC2s may represent a possible surrogate of advanced disease and poor prognosis. mDC2s are known to play a role that is more prominent than the other DC subsets in antigen presentation and induction of anti-tumour immunity. In particular, mDC2s are likely to be of great importance in the induction of T-helper type 1 cells and cytotoxic T lymphocyte immune responses, and excel in cross-presentation of soluble or cell-associated antigens to CD8 + T lymphocytes and CD8 + T cell priming for tumours, as directly compared with mDC1s and pDCs (Bachem et al, 2010; Jongbloed et al, 2010; Roberts et al, 2016) . Hence, the quantitative reduction we observed in our patients may be a factor of major relevance to the lack of tumour surveillance. Patients' pDC counts were reduced at baseline, as compared with healthy controls, had lower frequencies in case of B-symptoms and strikingly recovered into normal ranges upon treatment completion. Indeed, it is hard to comment on the relevance of these data given that it has recently been discovered that the traditionally-defined pDCs actually encompass distinct, even new, variants, each of which display specific functions and properties with regard to the ability of T-cell proliferation induction and cytokine production (See et al, 2017; Villani et al, 2017; Wilhelm et al, 2016; Zhang et al, 2017) .
The classification of DCs has been reviewed using singlecell transcriptome profiling; new DC subtypes have been discovered and a more comprehensive map of human blood DCs is available (Villani et al, 2017) . This updated DCs atlas has caused us to be cautious in interpreting statistically significant findings for the pDCs population in our study.
Conversely, mDC1 and mDC2 subsets remain in the recently revised DC classification, confirming their attributed functions and properties (Villani et al, 2017) . Boxplot showing the distribution of the percentages (top) and the sequential absolute counts (bottom) of mDC1, mDC2, and pDC subsets among total leucocytes in 26 classical Hodgkin lymphoma patients evaluated at diagnosis and at the end of chemotherapy treatment. P-values were obtained using Wilcoxon signed rank test. EoT, end of treatment; mDC1, myeloid dendritic cells type 1; mDC2, myeloid dendritic cells type 2; pDC, plasmacytoid dendritic cells.
Henceforward, we strongly suggest that mDC1 and mDC2 subsets warrant evaluations for putative pathobiological mechanisms of action in cHL and should be explored as potential biomarkers in this disease. Also, we believe that studies on the biological significance of mDC subsets in cHL will be of utmost importance in the very near future due to the substantial contribution of these cells to the PD1 (PDCD1/PD-L1 (CD274)/PD-L2 (PDCD1LG2) regulatory axis, the upregulation of which has emerged as a key oncogenic driver of cHL and a critical target for therapeutical intervention (Hawkes et al, 2015) . In this regard, data from a recent research conducted in mouse melanoma model documented that intratumoural CD103 + DCs, i.e. the murine counterpart of CD141 + DCs (mDC2) controlled anti-PD-L1-Ab-mediated anti-tumour immunity. Notably, PD-L1 inhibition led to a modest anti-tumour response, and this response was dramatically increased upon the expansion and activation of CD103 + DC at the tumour site (Salmon et al, 2016) .
In our study, the increase of the relative and absolute DC counts upon treatment completion was impressive and statistically meaningful for all three DC subsets studied. According to a previous report, these data suggest that conventional chemotherapy can modulate particular DC subtypes (Derolf et al, 2014) , although the different increases in the specific DC subsets highlights the complex interactions between effects of chemotherapy, immune reconstitution process and Hodgkin lymphoma.
To the best of our knowledge, the evidence of altered DC profiles in cHL has been uniquely studied in infiltrated tissues through gene profiling and immunochemistry.
Some of these profiling studies showed that signatures, reflecting overabundance and biological activity of pDC cells in cHL tissues, i.e. integral membrane protein 2A (ITM2A), sushi repeat containing protein (SRPX), cathepsin B (CTSB) and amyloid beta precursor protein (APP), were associated with adverse prognosis in terms of primary treatment outcome (Steidl et al, 2010 (Steidl et al, , 2011 ).
An immunohistochemical study of 61 patients suggested that cHL cases with high levels of tissue CD68 + macrophages and low levels of CD1a + immature mDC were associated with adverse prognostic parameters, such as advanced stage and widespread lymphadenopathy (Abdou et al, 2013) . The absence of CD1a + mDCs in lymphoma tissues was also significantly associated with a poor outcome. More recently, the putative prognostic role of mDCs was analysed in a large series of 106 patients with cHL (Tudor et al, 2014 (Tudor et al, 2014) . To date, there is a stringent need for trustworthy routine diagnostic biomarkers to empower the upfront identification of cHL patients who do not show a response to therapy. Due to the specific pathobiology of cHL, with the HRS neoplastic cells composing only a small part of the cellular tumour mass (Kuppers, 2009) , several studies in the last decade have focused on the surrounding inflammatory infiltrate, albeit with variable results, especially regarding prognostication (Steidl et al, 2011) . Similarly, the high inter-rate variability and subjective nature of immunohistochemical (i.e., tissue-based HRS-cell) biomarkers precluded the establishment of reliable tissuebased prognostic markers (Canioni et al, 2009) .
PET2-adapted strategies seem capable of rescuing at least 50% of PET2-positive patients, but PET2 negativity did not exclude the possibility of recurrence so an overall improvement in survival has been not evident so far. New costly agents are likely to be introduced across the board for all patients, independently of their risk profile.
In this regard, the absence of biological markers guiding the definition of risk in cHL is an important fact.
Our study suffers from drawbacks derived from the limits of the flow cytometric finding of small subpopulations in peripheral blood. Therefore, each laboratory should determine internal cut-offs based on healthy subjects. Also, our study did not investigate the DCs function and comparative data from blood and lymphoid organs were not available.
In conclusion, we provide evidence for a constitutive reduction of blood DC levels in patients with cHL at diagnosis that correlated with tumour burden and dissemination (mDC1 and mDC2 subsets) and/or disease activity (pDC subset). Notably, treatment completion and response achievement were associated with a statistically significant reconstitution of the circulating DC pool, unaffected by the presence of negative prognosticators. While patients with more compromised mDC2 levels showed a wider anatomical extent of disease, the analysis of larger cohorts is warranted to conclusively ascertain the prognostic impact of this finding.
Given the role of DCs in tumour recognition, these findings may be of relevance because the quantitative defect may contribute to a poor immune response and the escape of the malignant clone from immune surveillance.
In conclusion, our results suggest that DCs may contribute to the disturbed immunological interplay cells typical of cHL and prompt a further evaluation of their value as a potential new biomarker.
